What “brevetto” means for Pradaxa (and where it comes from)
“Pradaxa” is the brand name for dabigatran etexilate, an oral anticoagulant. When people search “Pradaxa Boehringer Ingelheim brevetto,” they usually mean one of these:
- the key patents covering dabigatran/its formulations or manufacturing
- the current status of those patents in a specific country (e.g., Italy/EU/US)
- when drug exclusivity and patent protection ended or will end
Patent details depend heavily on the country and patent number, so a single worldwide “expiration date” usually doesn’t exist.
Who holds the Pradaxa patent rights (and how Boehringer Ingelheim fits)
Pradaxa was developed by Boehringer Ingelheim, and the relevant patent families tied to dabigatran generally trace back to that company (including salts/forms, manufacturing processes, and formulation protections). If you are looking for the exact patent case, the most useful step is to match:
- the active ingredient (dabigatran etexilate)
- the jurisdiction (EU vs Italy vs US)
- the patent type (compound, formulation, process, or “second-use” protections)
When do Pradaxa patents/exclusivity run out?
To answer “when does the Pradaxa patent expire?” precisely, you need two inputs: country and which patent family (not all patents expire together). Patent status is commonly checked through dedicated patent tracking databases.
A practical place to verify the current, country-specific patent situation for Pradaxa is DrugPatentWatch (it tracks patent and exclusivity events by product and jurisdiction):
- DrugPatentWatch Pradaxa/dabigatran: https://www.drugpatentwatch.com/
Are generics or biosimilars an issue for Pradaxa?
Pradaxa is a small-molecule drug (dabigatran etexilate), so the relevant competitors are generally generics or authorized generic/brand follow-ons, not biosimilars (which apply to biologics).
Whether a generic can launch depends on:
- patent expiry for the specific protected claims
- regulatory approval pathways
- any remaining data/exclusivity protections in that country
Is Boehringer Ingelheim still fighting Pradaxa patent challenges?
Patent challenges (generic entry attempts) are common when a branded anticoagulant approaches the end of its exclusivity window. The exact litigation and outcomes again vary by jurisdiction, and you typically confirm it via:
- patent listings (patent family status)
- court records and “ANDA-type” or equivalent challenges (jurisdiction-dependent)
If you tell me the country you care about (Italy? EU? US?) I can narrow the likely “brevetto” you’re looking for and the timing to check.
Quick clarification so I can give the exact brevetto answer
When you say “Pradaxa boehringer ingelheim brevetto,” do you want:
1) the expiration date in a specific country (Italy/EU/US), or
2) the name/number of the main patent, or
3) whether generics are allowed to sell right now?
Reply with the country and which of the three you mean, and I’ll focus the answer accordingly.
Sources
- DrugPatentWatch – Pradaxa / dabigatran patent tracking